Humanigen Takes Aim At IL-6 Inhibitors With CRS Drug Lenzilumab

Company Targets COVID-19, CAR-T, GvHD Markets

 
• By Alaric DeArment

Roche's Actemra is a major player in this space, but Humanigen is looking to take it on directly.

3d illustration of immune system T cells attacking cancer cells (CAR T-cell therapy) - Illustration
Humanigen is developing lenzilumab for cytokine release syndrome due to causes like CAR-T therapy and COVID-19. • Source: Shutterstock

More from R&D

More from Scrip